Cargando…
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
BACKGROUND: Although MYC is an attractive therapeutic target for breast cancer treatment, it has proven challenging to inhibit MYC directly, and clinically effective pharmaceutical agents targeting MYC are not yet available. An alternative approach is to identify genes that are synthetically lethal...
Autores principales: | Kang, Jian, Sergio, C Marcelo, Sutherland, Robert L, Musgrove, Elizabeth A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903446/ https://www.ncbi.nlm.nih.gov/pubmed/24444383 http://dx.doi.org/10.1186/1471-2407-14-32 |
Ejemplares similares
-
Cyclin-Dependent
Kinase (CDK) Inhibitors: Structure–Activity
Relationships and Insights into the CDK-2 Selectivity of 6-Substituted
2-Arylaminopurines
por: Coxon, Christopher R., et al.
Publicado: (2016) -
Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors
por: Sofi, Shazia, et al.
Publicado: (2022) -
The Cyclin-dependent Kinase Cdk2 Regulates Thymocyte Apoptosis
por: Hakem, Anne, et al.
Publicado: (1999) -
Cyclin-dependent kinases and CDK inhibitors in virus-associated cancers
por: Tavakolian, Shaian, et al.
Publicado: (2020) -
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
por: Łukasik, Paweł, et al.
Publicado: (2021)